Author:
Facchini Ludovica,Lucchesi Maurizio,Stival Alessia,Roperto Rosa Maria,Melosi Francesca,Materassi Marco,Farina Silvia,Tintori Veronica,de Martino Maurizio,Sardi Iacopo
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858–66.
2. Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61:289–99.
3. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20:518–25.
4. Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol. 2014;5:30–3.
5. Lee HW, Chung MJ, Kang H, Choi H, Choi YJ, Lee KJ, et al. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the Literature. Gut Liver. 2014;8:109–12.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献